TRAX Stock Forecast & Price Target

First Tracks is showcasing strong potential with its clinical-stage pipeline, particularly with their treatments ANB033 and ANB101 targeting various inflammatory diseases. With a diversity of potential treatments and strong focus on research and development, the company is well-equipped to compete in the market. However, investors should also consider the company's competition and financial needs, as well as the use of a 12% discount rate and -25% terminal growth rate in calculating FCFF for the company.

First Tracks is still in the early stages of its clinical trials for its pipeline of immunology therapeutics, and its lack of in-house manufacturing capabilities makes it susceptible to delays and setbacks. Furthermore, the company's potential competitors have shown positive results in similar trials for autoimmune diseases, making it difficult for First Tracks to differentiate itself in the market. Additionally, the company's estimated commercial launch in 2029 and treatment price of $55,000 may not be competitive compared to other therapies on the market by that time.